Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) reached a new 52-week high during trading on Tuesday . The company traded as high as $30.59 and last traded at $29.90, with a volume of 557250 shares traded. The stock had previously closed at $28.00.
Wall Street Analyst Weigh In
PAHC has been the subject of a number of research reports. JPMorgan Chase & Co. upgraded shares of Phibro Animal Health from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $25.00 to $35.00 in a report on Monday. Morgan Stanley set a $26.00 target price on Phibro Animal Health and gave the stock an "equal weight" rating in a report on Wednesday, June 25th. BNP Paribas raised Phibro Animal Health to a "hold" rating in a research report on Monday, June 16th. BNP Paribas Exane raised Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target on the stock in a research note on Monday, June 16th. Finally, Wall Street Zen upgraded Phibro Animal Health from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $24.40.
View Our Latest Stock Report on Phibro Animal Health
Phibro Animal Health Price Performance
The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of 40.24, a price-to-earnings-growth ratio of 0.50 and a beta of 0.75. The company has a current ratio of 2.91, a quick ratio of 1.23 and a debt-to-equity ratio of 2.67. The stock has a 50-day simple moving average of $24.06 and a 200 day simple moving average of $22.25.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.52 by $0.11. Phibro Animal Health had a net margin of 2.68% and a return on equity of 30.51%. The firm had revenue of $347.80 million for the quarter, compared to the consensus estimate of $352.41 million. On average, equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.
Phibro Animal Health Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 25th. Investors of record on Wednesday, June 4th were given a dividend of $0.12 per share. The ex-dividend date was Wednesday, June 4th. This represents a $0.48 dividend on an annualized basis and a yield of 1.53%. Phibro Animal Health's payout ratio is 61.54%.
Institutional Investors Weigh In On Phibro Animal Health
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC grew its stake in shares of Phibro Animal Health by 2.4% in the 4th quarter. Sterling Capital Management LLC now owns 18,762 shares of the company's stock valued at $394,000 after buying an additional 448 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company's stock worth $260,000 after acquiring an additional 546 shares in the last quarter. Algert Global LLC increased its stake in shares of Phibro Animal Health by 1.4% during the 1st quarter. Algert Global LLC now owns 97,612 shares of the company's stock worth $2,085,000 after purchasing an additional 1,340 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Phibro Animal Health in the 4th quarter valued at $29,000. Finally, National Bank of Canada FI bought a new stake in Phibro Animal Health in the first quarter worth $30,000. 99.34% of the stock is owned by hedge funds and other institutional investors.
About Phibro Animal Health
(
Get Free Report)
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
See Also
Before you consider Phibro Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.
While Phibro Animal Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
